Cited by 167Glioma Diagnosis and TreatmentAcute Lymphoblastic Leukemia researchNeuroblastoma Research and Treatments

The DOI matches its Crossref record, with a small difference in title or year; 33 of the 34 references it cites were found in a registry or an index, and 1 are not checked yet.

Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children’s Oncology Group

Open access

Leary, Sarah E. S., Packer, Roger J., Li, Yimei, Billups, Catherine A., Smith, Kyle S., Jaju, Alok, Heier, Linda, Burger, Peter, Walsh, Karin, Han, Yuanyuan, Embry, Leanne, Hadley, Jennifer, Kumar, Rahul, Michalski, Jeff, Hwang, Eugene, Gajjar, Amar, Pollack, Ian F., Fouladi, Maryam, Northcott, Paul A., Olson, James M.·2021·JAMA Oncology

DOI 10.1001/jamaoncol.2021.2224PMC PMC8299367

Open this paper in CoChat — free account Open PDF

Abstract

IMPORTANCE: Brain tumors are the leading cause of disease-related death in children. Medulloblastoma is the most common malignant embryonal brain tumor, and strategies to increase survival are needed. OBJECTIVE: To evaluate therapy intensification with carboplatin as a radiosensitizer and isotretinoin as a proapoptotic agent in children with high-risk medulloblastoma in a randomized clinical trial and, with a correlative biology study, facilitate planned subgroup analysis according to World Health Organization consensus molecular subgroups of medulloblastoma. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical phase 3 trial was conducted from March 2007 to September 2018. Analysis was completed in September 2020. Patients aged 3 to 21 years with newly diagnosed high-risk medulloblastoma from Children's Oncology Group institutions within the US, Canada, Australia, and New Zealand were included. High-risk features included metastasis, residual disease, or diffuse anaplasia. INTERVENTIONS: Patients were randomized to receive 36-Gy craniospinal radiation therapy and weekly vincristine with or without daily carboplatin followed by 6 cycles of maintenance chemotherapy with cisplatin, cyclophosphamide, and vincristine with or without 12 cycles of isotretinoin during and following maintenance. MAIN OUTCOMES AND MEASURES: The primary clinical trial end point was event-free survival, using the log-rank test to compare arms. The primary biology study end point was molecular subgroup classification by DNA methylation array. RESULTS: Of 294 patients with medulloblastoma, 261 were evaluable after central radiologic and pathologic review; median age, 8.6 years (range, 3.3-21.2); 183 (70%) male; 189 (72%) with metastatic disease; 58 (22%) with diffuse anaplasia; and 14 (5%) with greater than 1.5-cm2 residual disease. For all participants, the 5-year event-free survival was 62.9% (95% CI, 55.6%-70.2%) and overall survival was 73.4% (95% CI, 66.7%-80.1%). Isotretinoin randomization was closed early owing to futility. Five-year event-free survival was 66.4% (95% CI, 56.4%-76.4%) with carboplatin vs 59.2% (95% CI, 48.8%-69.6%) without carboplatin (P = .11), with the effect exclusively observed in group 3 subgroup patients: 73.2% (95% CI, 56.9%-89.5%) with carboplatin vs 53.7% (95% CI, 35.3%-72.1%) without (P = .047). Five-year overall survival differed by molecular subgroup (P = .006): WNT pathway activated, 100% (95% CI, 100%-100%); SHH pathway activated, 53.6% (95% CI, 33.0%-74.2%); group 3, 73.7% (95% CI, 61.9%-85.5%); and group 4, 76.9% (95% CI, 67.3%-86.5%). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, therapy intensification with carboplatin improved event-free survival by 19% at 5 years for children with high-risk group 3 medulloblastoma. These findings further support the value of an integrated clinical and molecular risk stratification for medulloblastoma. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00392327.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2021.2224

Cites

33 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella‐Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,703
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063
DNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chávez, L., Reuß, D., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,114
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
Ostrom, Q. T., Gittleman, H. R., Fulop, J., Liu, M. B., Blanda, R., Kromer, C. M., Wolinsky, Y., Kruchko, C., & Barnholtz‐Sloan, J. S. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov189 · Cited by 2,228
Molecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936
Self-citation
Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K. C., Swift, P. S., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,891
Medulloblastoma Comprises Four Distinct Molecular Variants
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S. C., Bouffet, É., Clifford, S. C., Hawkins, C. E., French, P. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4324 · Cited by 1,353
Self-citation
The whole-genome landscape of medulloblastoma subtypes
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature · doi:10.1038/nature22973 · Cited by 1,112
Self-citation
Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma
Packer, R. J., Gajjar, A. J., Vézina, G., Rorke-Adams, L. B., Burger, P. C., Robertson, P. L., Bayer, L. A., Lafond, D. A., Donahue, B. R., Marymont, M. H., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4980 · Cited by 985
Self-citation
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial
Gajjar, A. J., Chintagumpala, M., Ashley, D. M., Kellie, S. J., Kun, L. E., Merchant, T. E., Woo, S. Y., Wheeler, G., Ahern, V., Krasin, M. J., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70867-1 · Cited by 951
Self-citation

Show all 34 references

Sorted by citations

Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
Horbinski, C., Berger, T., Packer, R. J., & Wen, P. Y. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00679-w · Cited by 312
Self-citation
Medulloblastoma: Current Perspectives and Recent Advances
Choi, J. Y. (2023) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2022.0046 · Cited by 75
Childhood Malignant Brain Tumors: Balancing the Bench and Bedside
Thorbinson, C., & Kilday, J. (2021) · Cancers · doi:10.3390/cancers13236099 · Cited by 63
Medulloblastoma in the Modern Era: Review of Contemporary Trials, Molecular Advances, and Updates in Management
Lazow, M., Palmer, J. D., Fouladi, M., & Salloum, R. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01273-0 · Cited by 58
Self-citation
Recent Advances in Pediatric Medulloblastoma
Jackson, K., & Packer, R. J. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01316-9 · Cited by 53
Self-citation
SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma
Mynarek, M., Milde, T., Padovani, L., Janssens, G. O. R. J., Kwiecien, R., Mosseri, V., Clifford, S. C., Doz, F., & Rutkowski, S. (2021) · Cancers · doi:10.3390/cancers13236077 · Cited by 49
Radiotherapy in Medulloblastoma—Evolution of Treatment, Current Concepts and Future Perspectives
Seidel, C., Heider, S., Hau, P., Glasow, A., Dietzsch, S., & Kortmann, R. (2021) · Cancers · doi:10.3390/cancers13235945 · Cited by 48
New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma
Fang, F. Y., Rosenblum, J. S., Ho, W. S., & Heiss, J. D. (2022) · Cancers · doi:10.3390/cancers14092285 · Cited by 48
Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment
Ray, S., Chaturvedi, N. K., Bhakat, K. K., Rizzino, A., & Mahapatra, S. (2021) · Diagnostics · doi:10.3390/diagnostics12010061 · Cited by 49
Adolescents and Young Adults With Cancer: CNS Tumors
Wu, J., Heidelberg, R. E., & Gajjar, A. J. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01747 · Cited by 38
Self-citation
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation–Sparing Approaches: An International Cohort Study
Erker, C. A., Mynarek, M., Bailey, S., Mazewski, C., Baroni, L., Massimino, M., Hukin, J., Aguilera, D. G., Cappellano, A. M., Ramaswamy, V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02968 · Cited by 32
Self-citation
Posterior fossa tumors in children: current insights
Formentin, C., Joaquim, A. F., & Ghizoni, E. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-05189-5 · Cited by 33
Brain gliomas: Diagnostic and therapeutic issues and the prospects of drug-targeted nano-delivery technology
Song, B., Wang, X., Qin, L., Hussain, S., & Liang, W. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107308 · Cited by 31
Glioma-targeted oxaliplatin/ferritin clathrate reversing the immunosuppressive microenvironment through hijacking Fe2+ and boosting Fenton reaction
Li, X., Cheng, Y., Yang, Z., Ji, Q., Huan, M., Ye, W., Liu, M., Zhang, B., Liu, D., & Zhou, S. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02376-w · Cited by 29
Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group
Cooney, T., Lindsay, H., Leary, S. E. S., & Wechsler‐Reya, R. J. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100861 · Cited by 28
Self-citation
Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country
Amayiri, N. Y., Swaidan, M., Ibrahimi, A., Hirmas, N., Musharbash, A. F., Bouffet, É., Al-Hussaini, M. A., & Ramaswamy, V. (2021) · JCO Global Oncology · doi:10.1200/go.21.00127 · Cited by 25
Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference Network
Bailey, S., Jacobs, S. A., Kourti, M., Massimino, M., André, N., Doz, F., Dufour, C., Vennarini, S., Padovani, L., Aquilina, K., et al. (2024) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2024.100205 · Cited by 26
Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children’s Oncology Group
Mazewski, C., Leary, S. E. S., Kang, G., Li, B. K., Kellie, S. J., Hayes, L. L., Shaw, D., Ho, B., Reddy, A. T., Gossett, J. M., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf132 · Cited by 24
Self-citation
Clinical outcome of pediatric medulloblastoma patients with Li–Fraumeni syndrome
Kolodziejczak, A. S., Guerrini‐Rousseau, L., Masliah‐Planchon, J., Ecker, J., Selt, F., Mynarek, M., Obrecht, D., Sill, M., Autry, R. J., Stutheit-Zhao, E., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad114 · Cited by 26
Chemotherapy in pediatric brain tumor and the challenge of the blood–brain barrier
Reza, M. J., Podany, A. T., Κhan, P., Shaffer, C. L., Siddiqui, J. A., Baranowska‐Kortylewicz, J., Lê, J., Fletcher, C. V., Ether, S. A., & Avedissian, S. N. (2023) · Cancer Medicine · doi:10.1002/cam4.6647 · Cited by 22
Cross-translational models of late-onset cognitive sequelae and their treatment in pediatric brain tumor survivors
Dahhan, N. Z. A., Cox, E., Nieman, B. J., & Mabbott, D. (2022) · Neuron · doi:10.1016/j.neuron.2022.04.009 · Cited by 23
The clinical significance of sub-total surgical resection in childhood medulloblastoma: a multi-cohort analysis of 1100 patients
Keeling, C., Davies, S., Goddard, J., Ramaswamy, V., Schwalbe, E. C., Bailey, S., Hicks, D., & Clifford, S. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102469 · Cited by 19
Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment
Rechberger, J. S., Toll, S. A., Vanbilloen, W. J. F., Daniels, D. J., & Khatua, S. (2023) · Diagnostics · doi:10.3390/diagnostics13142398 · Cited by 19
Treatment of hydrocephalus following posterior fossa tumor resection: a multicenter collaboration from the Hydrocephalus Clinical Research Network
Dewan, M. C., Isaacs, A. M., Cools, M. J., Yengo-Kahn, A. M., Naftel, R. P., Jensen, H., Reeder, R., Holubkov, R., Haizel‐Cobbina, J., Riva-Cambrin, J. K., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04316-4 · Cited by 15
Self-citation
Surviving the hunger games: Metabolic reprogramming in medulloblastoma
Manfreda, L., Rampazzo, E., Persano, L., Viola, G., & Bortolozzi, R. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115697 · Cited by 15
Current Strategies for Management of Medulloblastoma
Prados, M. D. (2023) · Diagnostics · doi:10.3390/diagnostics13162622 · Cited by 17
Smart Design of Targeted Drug Delivery System for Precise Drug Delivery and Visual Treatment of Brain Gliomas
Song, B., Wu, M., Qin, L., Liang, W., & Wang, X. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402967 · Cited by 15
Evolution of Systemic Therapy in Medulloblastoma Including Irradiation-Sparing Approaches
Mushtaq, N., Ain, R. U., Hamid, S. A., & Bouffet, É. (2023) · Diagnostics · doi:10.3390/diagnostics13243680 · Cited by 13
OLIG2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma
Desai, K., Wanggou, S., Luis, E., Whetstone, H., Yu, C., Vanner, R. J., Selvadurai, H. J., Lee, L., Vijay, J., Jaramillo, J. E., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54858-y · Cited by 16
Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors
Leary, S. E. S., Onar‐Thomas, A., Fangusaro, J., Gottardo, N. G., Cohen, K. J., Smith, A., Huang, A., Haas-Kogan, D. A., & Fouladi, M. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30600 · Cited by 13
Self-citation
Advancing medulloblastoma therapy: strategies and survival insights
Pan, Z., Bao, J., & Wei, S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01648-5 · Cited by 12
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment
Santos, R. D., Ruzza, A., Wang, B., Maruff, P. T., Schembri, A. J., Bhatia, A. K., Mach, F., Bergeron, J., Gaudet, I., St‐Pierre, J., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad332 · Cited by 12
Disease Evolution Monitored by Serial Cerebrospinal Fluid Liquid Biopsies in Two Cases of Recurrent Medulloblastoma
O’Halloran, K., Margol, A., Davidson, T. B., Estrine, D. B., Tamrazi, B., Cotter, J. A., Ji, J., & Biegel, J. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094882 · Cited by 11
Multiparametric MRI-based machine learning system of molecular subgroups and prognosis in medulloblastoma
Liu, Z., Ren, S., Zhang, H., Liao, Z., Liu, Z., An, X., Cheng, J., Li, C., Gong, J. F., Niu, H., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11385-8 · Cited by 11
EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression
Wolin, A. R., Vincent, M. Y., Hotz, T. J., Purdy, S. C., Rosenbaum, S. R., Hughes, C. J., Hsu, J. Y., Oliphant, M. U. J., Armstrong, B. A., Wessells, V. M., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad128 · Cited by 11
Factors influencing outcomes of older children with medulloblastoma over 15 years in Peru, a resource‐limited setting
Coronado, R. Y. D., Reinecke, J. B., Stanek, J. R., Finlay, J. L., Hernández, E., Chávez, S., Tunque, Y. M., Zelaya, A. H., Casavilca-Zambrano, S. A., García-Corrochano, P., et al. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29770 · Cited by 11
Pediatric Central Nervous System Embryonal Tumors: Presentation, Diagnosis, Therapeutic Strategies, and Survivorship—A Review
Ronsley, R. J., Cole, B., Ketterl, T. G., Wright, J. N., Ermoian, R. P., Hoffman, L. M., Margol, A., & Leary, S. E. S. (2024) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2024.09.031 · Cited by 10
Self-citation
Radiotherapy for Primary Pediatric Central Nervous System Malignancies: Current Treatment Paradigms and Future Directions
Liu, K. X., Haas-Kogan, D. A., & Elhalawani, H. M. (2023) · Pediatric Neurosurgery · doi:10.1159/000533777 · Cited by 10
The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma
Ghasemi, D. R., Fleischhack, G., Milde, T., & Pajtler, K. W. (2022) · Cancers · doi:10.3390/cancers14030679 · Cited by 11
Changes to pediatric brain tumors in 2021 World Health Organization classification of tumors of the central nervous system
Öztek, M. A., Noda, S. M., Romberg, E. K., Cole, B., Wright, J. N., Ishak, G. E., & Perez, F. A. (2022) · Pediatric Radiology · doi:10.1007/s00247-022-05546-w · Cited by 10
Hypogonadism After Treatment for Medulloblastoma: Results From the SJMB03 Trial of Risk-Adapted Radiation Therapy
Merchant, T. E., Wu, S., Onar‐Thomas, A., Gajjar, A. J., & Delaney, A. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.01.001 · Cited by 9
Self-citation
Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours
Seiboldt, T., Zeiser, C., Nguyen, D., Çelikyürekli, S., Herter, S., Najafi, S., Stroh-Dege, A., Meulenbroeks, C., Mack, N. L., Salem-Altintas, R., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02740-5 · Cited by 11
Advancing Medulloblastoma Therapy in Pediatrics: Integrative Molecular Classification and Emerging Treatments
Kim, D. T., Uloho-Okundaye, M., Frederico, S. C., Guru, S., Kim, M. J., & Chang, S. D. (2025) · Brain Sciences · doi:10.3390/brainsci15080896 · Cited by 10
Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir
Gringmuth, M., Walther, J., Greiser, S., Toussaint, M., Schwalm, B., Kool, M., Kortmann, R., Glasow, A., & Patties, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073815 · Cited by 9
Review of the impact of molecular analysis on the therapy of medulloblastoma
Sarvode, S., & Gajjar, A. J. (2023) · Pediatric Hematology Oncology Journal · doi:10.1016/j.phoj.2023.05.001 · Cited by 9
Self-citation
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
Zhu, X.-Z., Zhang, H.-Y.-L., Zhou, Y.-F., Chen, Y.-Y., Fu, T., Jin, M.-L., Zhao, Y.-X., Xie, Y.-F., Zeng, X., Jin, X., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-5002 · Cited by 8
An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival
Smith, K. S., Dhanda, S. K., Billups, C. A., Sioson, E., Lu, C., Peraza, A. Z., Gangwani, K., Li, Y., Li, Q., Lin, T., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf250 · Cited by 8
Self-citation
How do we approach the management of medulloblastoma in young children?
Lafay‐Cousin, L., Baroni, L., Ramaswamy, V., & Bouffet, É. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29838 · Cited by 9
Identification and validation of a novel HOX-related classifier signature for predicting prognosis and immune microenvironment in pediatric gliomas
Zhang, J., Zhang, X., Su, J., Zhang, J., Liu, S., Li, H., Liu, M., & Sun, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1203650 · Cited by 7
Temporal changes in childhood cancer incidence and survival by stage at diagnosis in Australia, 2000–2017
Youlden, D. R., Baade, P. D., Frazier, A. L., Gupta, S., Gottardo, N. G., Moore, A. S., & Aitken, J. F. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2251668 · Cited by 7
Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype
Massimino, M., Barretta, F., Dossena, C., Minasi, S., Buttarelli, F. R., Biassoni, V., Oriani, M., Schiavello, E., Ficorilli, M., Nigro, O., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae189 · Cited by 7
Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study
Lucas, J. T., Tinkle, C. L., Huang, J., Onar‐Thomas, A., Srinivasan, S., Tumlin, P., Becksfort, J. B., Klimo, P. D., Boop, F. A., Robinson, G. W., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab284 · Cited by 7
Self-citation
Questions and answers in the management of children with medulloblastoma over the time. How did we get here? A systematic review
Osuna‐Marco, M. P., Martín‐López, L. I., Tejera, Á. M., & López‐Ibor, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1229853 · Cited by 7
Targeting synthetic lethality between non-homologous end joining and radiation in very-high-risk medulloblastoma
DeCarlo, A., MacLeod, G. D. A. H., da Silva, C. F., Shen, L., Povilaikaite, J., Deane, M., Aragao, L., Sie, M., Termini, D., Magee, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102202 · Cited by 6
Self-citation
Medulloblastoma: Current Standard of Care and Future Treatment Opportunities
Mayr, L., Azizi, A. A., Gojo, J., & Peyrl, A. (2025) · Pediatric Drugs · doi:10.1007/s40272-025-00726-1 · Cited by 6
Systematic transcriptomic analysis of childhood medulloblastoma identifies N6-methyladenosine-dependent lncRNA signatures associated with molecular subtype, immune cell infiltration, and prognosis
Joshi, K., Yuan, M., Katsushima, K., Saulnier, O., Ray, A., Amankwah, E. K., Stapleton, S. L., Jallo, G. I., Taylor, M. D., Eberhart, C. G., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01848-2 · Cited by 6
Medulloblastoma Molecular Subgrouping and Outcomes Data of a Single Center From a Low‐ and Middle‐Income Country
Mushtaq, N., Bashir, F., Zahid, S., Riaz, Q., Javed, G., Tariq, M., Qureshi, B. M., Hilal, K., Ramaswamy, V., Hawkins, C. E., et al. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31555 · Cited by 6
Therapeutic radiation drives leptomeningeal dissemination of medulloblastoma through an innate immune process
Nör, C., Kharas, K., Rasnitsyn, A., Vladoiu, M. C., Cho, N. W., Young, J. S., Nör, F., Mankahla, N., Haapasalo, J. A., Nordfors, K., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.06.016 · Cited by 7
Effects of different molecular subtypes and tumor biology on the prognosis of medulloblastoma
Aras, Y., Dölen, D., Çelik, A. İ., Kayhan, G. K., Kebudi, R., Ünverengil, G., Sabancı, P. A., & İzgi, N. (2021) · Child s Nervous System · doi:10.1007/s00381-021-05350-1 · Cited by 6
Clinico-Radiological Outcomes in WNT-Subgroup Medulloblastoma
Mani, S., Chatterjee, A., Dasgupta, A., Shirsat, N. V., Pawar, A., Epari, S., Sahay, A., Sahu, A., Moiyadi, A. V., Prasad, M., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14040358 · Cited by 5
Targeting processive transcription for Myc-driven circuitry in medulloblastoma
Sobral, L. M., Walker, F. M., Madhavan, K. P. C., Janko, E., Donthula, S., Danis, E. P., Bompada, P., Balakrishnan, I., Wang, D., Pierce, A. M., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf121 · Cited by 5
Current Open Trials and Molecular Update for Pediatric Embryonal Tumors
Rosenberg, T., & Cooney, T. M. (2023) · Pediatric Neurosurgery · doi:10.1159/000531256 · Cited by 5
Prognostic significance of molecular subgroups in survival outcome for children with medulloblastoma in Malaysia
Rajagopal, R., Teng, A. J., Jawin, V., Wong, O. L., Mahsin, H., Rani, N. H. A., Yap, T. Y., Gunasagaran, K., Thevarajah, A., Yeoh, S. L., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1278611 · Cited by 5
Long-term Outcomes of Protocol-Based Treatment for Newly Diagnosed Medulloblastoma
Ahn, W. K., Hahn, S. M., Yoon, H. I., Lee, J., Park, E. K., Shim, K., Kim, D. S., Suh, C., Kim, S. H., Lyu, C. J., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.865 · Cited by 5
Risk-stratification for treatment de-intensification in WNT-pathway medulloblastoma: finding the optimal balance between survival and quality of survivorship
Gupta, T., Mani, S., Chatterjee, A., Dasgupta, A., Epari, S., & Chinnaswamy, G. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2357807 · Cited by 5
Infant brain tumor trials: Beyond feasibility
Bouffet, É., & Lafay‐Cousin, L. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac065 · Cited by 5
When Can We Retire 3,600 cGy Craniospinal Irradiation in Medulloblastoma?
Fisher, P. G. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00008 · Cited by 5
Medulloblastoma Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity with High-Density Progenitor Cell Regions Correlating with High-Risk DiseasePreprint
Chien, F., Michaud, M. E., Bakhtiari, M., Schroff, C., Snuderl, M., Vega, J. E. V., MacDonald, T. J., & Bhasin, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.25.600684 · Cited by 5
Integration of immunohistochemistry, RNA sequencing, and multiplex ligation‐dependent probe amplification for molecular classification of pediatric medulloblastoma
Huang, H., Yu, C., Yang, Y., Chang, Y., Jou, S., Lin, K., Lu, M., Chang, H., Chou, S., Ni, Y., et al. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29569 · Cited by 4
B7-H6 enhances F-actin rearrangement by targeting c-MYC activation to promote medulloblastoma migration and invasion
Fan, J., Wang, Y., Liang, X., Peng, Y., Li, S., Li, X., Zhou, F., & Li, Y. (2023) · Medical Oncology · doi:10.1007/s12032-023-01947-5 · Cited by 4
Self-citation
Treatment of Medulloblastoma in the Adolescent and Young Adult Population: A Systematic Review
Otth, M., Weiser, A., Lee, S.-Y., von Rohr, L. R., Heesen, P., Stücklin, A. G., & Scheinemann, K. (2024) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2024.0044 · Cited by 4
The Current Landscape of Molecular Pathology for the Diagnosis and Treatment of Pediatric Medulloblastoma
Koch, A., Childress, A., Vallee, E., Steller, A., & Raskin, S. I. (2025) · Journal of Molecular Pathology · doi:10.3390/jmp6020011 · Cited by 4
Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma—A New Standard of Care?—Reply
Leary, S. E. S., Li, Y., & Olson, J. M. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.6526 · Cited by 4
Self-citation
Impact of radiation response on survival in pediatric medulloblastoma with residual or disseminated disease
Shi, X., Sun, X., Fan, W., Dai, X., & Jiang, M. (2025) · Radiation Oncology · doi:10.1186/s13014-025-02632-9 · Cited by 3
Prior therapy defines mutation profiles in childhood cancer at relapse
Layeghifard, M., Díaz‐Gay, M., Bergstrom, E. N., Mahendralingam, M. J., Light, N., Blay, S., Nash, J. O., Anderson, N. D., Au, J. N., Davidson, S., et al. (2026) · Nature · doi:10.1038/s41586-026-10803-1 · Cited by 5
Successful Implementation of Image-Guided Pencil-Beam Scanning Proton Therapy in Medulloblastomas
Das, A., Gaikwad, U., Ganapathy, K., Rajendran, A., Patil, S., Subramaniam, P., Krishna, U., Wakde, M., Chilukuri, S. C., & Jalali, R. (2023) · Diagnostics · doi:10.3390/diagnostics13213378 · Cited by 3
Children's Oncology Group's 2023 blueprint for research: Radiation oncology
Kalapurakal, J. A., Wolden, S. L., Haas-Kogan, D. A., Laack, N. N., Hua, C., Paulino, A. C., Hill‐Kayser, C. E., Hoppe, B. S., & FitzGerald, T. J. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30593 · Cited by 3
Fatal brainstem injury following proton radiation in a patient with medulloblastoma and a germline variant in RNF213
Klawinski, D. M., Cottrell, C. E., Schieffer, K. M., Indyk, J. A., Gandhi, K. K., Mardis, E. R., Rodriguez, D. P., Breneman, J. C., & Osorio, D. S. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30739 · Cited by 3
Outcomes following radiation therapy for embryonal tumor with multilayered rosettes (ETMR): results from the Pediatric Proton/Photon Consortium Registry (PPCR)
Krisch, J. M., Ermoian, R. P., Indelicato, D. J., Lee, J. Y., Perentesis, J. P., Perkins, S. M., Laack, N. N., Chang, J. H. C., MacEwan, I. J., Wolden, S. L., et al. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05065-2 · Cited by 3
A cycling, progenitor-like cell population at the base of atypical teratoid rhabdoid tumor subtype differentiation trajectories
Blanco-Carmona, E., Paassen, I., He, J., DeMartino, J., Büllesbach, A., Anderson, N., Buhl, J. L., Federico, A., Mauermann, M., Brok, M. O., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf179 · Cited by 7
Management of pediatric brain tumors in low- and middle-income countries
Amayiri, N. Y., Mushtaq, N., Ghalibafian, M., & Bouffet, É. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.08.004 · Cited by 2
GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts
Okada, R., Fanuzzi, M., Rodríguez, C., Oh, J., Sreenivasan, A., Stack, H. G., Puebla, M., Phadke, I., Cole, A. P., Bradford, S. Y. C., et al. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201067 · Cited by 3
Surgical management and outcome of medulloblastoma patients at Addis Ababa between 2010 and 2018
Akililu, Y. B., Bouffet, É., & Abebe, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1672757 · Cited by 2
Medulloblastoma in Adolescents and Young Adults: Molecular Subgroups, Prognostic Biomarkers, and Age-Specific Therapeutic Challenges
Ruggiero, A., Gessi, M., d’Amati, A., Albanese, A., & Attinà, G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48030297 · Cited by 2
YAP1–MAML2 Fusion in Young Children With Pediatric High‐Grade Glioma: A Case Report
Thomson, N., Jewels, E., Bergeron‐Gravel, S., Lagacé, S., Hazrati, L., Saikali, S., Dunham, C. P., & Cheng, S. S. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31796 · Cited by 2
Isotretinoin as a Multifunctional Anticancer Agent: Molecular Mechanisms, Pharmacological Insights and Therapeutic Potential
Sarkar, P., Sultana, N., Debnath, P. K., Rouf, R., Mubarak, M. S., Uddin, S. J., Popa, D., Călina, D. C., & Sharifi‐Rad, J. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70084 · Cited by 3
Molecular and clinical correlates of medulloblastoma subgroups
Coltin, H., & Ramaswamy, V. (2021) · Glioma · doi:10.4103/glioma.glioma_18_21 · Cited by 2
Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas: “it’s a numbers game”—implications for WNT medulloblastoma dose-reduction clinical trials
Gottardo, N. G. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02518-0 · Cited by 2
International experience by using of the SJMB protocols in treatment of children with medulloblastoma in the age group over 3 years (literature review)
Levashov, A., Рустамовна, З. С., Valiev, T. T., Строганова, А. М., Khochenkov, D. A., Grigorenko, V. A., Михайлова, Е. В., Тюрина, E. В., Ryzhova, M. V., Horielyshev, S. K., et al. (2023) · Journal of Modern Oncology · doi:10.26442/18151434.2023.3.202437 · Cited by 2
The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients
Gangwani, K., Lu, C., Dhanda, S. K., Sioson, E., Zaldívar Peraza, A., Matt, G. Y., Paul, R., Wang, J., Reilly, C., Acić, A., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4976 · Cited by 1
Self-citation
You cannot diagnose what you cannot see: The importance of optimized imaging protocols for accurate disease staging and assessment
Gottardo, N. G., Fouladi, M., & Shaw, D. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30552 · Cited by 1
Self-citation
Isotretinoin has no effect on event-free survival across high-risk medulloblastoma molecular groups when added to maintenance: A secondary analysis of the Children's Oncology Group ACNS0332 data
Raskin, S. I., de Blank, P. M. K., Billups, C. A., Li, Y., Olson, J. M., & Leary, S. E. S. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf054 · Cited by 1
Self-citation
Feasibility and Outcomes of Craniospinal Irradiation and Concurrent Daily Carboplatin in Children and Adults With High-risk Central Nervous System Tumours
Singer, R., Lorimer, C., Welsh, L. C., Carceller, F., Vaidya, S. J., Marshall, L. V., Stone, J. R., Evans, R., O’Leary, B., Zacharoulis, S., et al. (2025) · Clinical Oncology · doi:10.1016/j.clon.2025.103866 · Cited by 1
Cerebrospinal fluid liquid biopsy guides differential diagnosis of relapsed medulloblastoma versus secondary glioma: A case report of a pediatric patient enrolled on a PDGFRA inhibitor trial
Fischer, T. T., Maaß, K. K., Schoof, M., Puranachot, P., Sievers, P., Montigel, S. H., Fluhr, T. L., Damaty, A. E., Seitz, A., Harrabi, S., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf110 · Cited by 1
Old Tools in a New Era: The Continued Relevance of Chemotherapy in Pediatric Neuro-Oncology
Felton, K. E. A., Lafay‐Cousin, L., & Cheng, S. S. (2025) · Current Oncology · doi:10.3390/curroncol32070410 · Cited by 1
Challenges and opportunities for treatment of medulloblastoma
Mehta, M., Somasundaram, D. B., Munshi, A., & Ramesh, R. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.06.006 · Cited by 1
Severe Hearing Loss in Children With Central Nervous System Tumors: A Population‐Based Cancer in Young People in Canada (CYP‐C) Report
Coltin, H., Trudeau-Ferrin, O., Perreault, S., Lafay‐Cousin, L., Tsang, D. S., Renzi, S., Larouche, V., Erker, C. A., Hukin, J., Barber, R., et al. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.32024 · Cited by 1
Exploring deep learning and hybrid approaches in molecular subgrouping and prognostic-related genetic signatures of medulloblastoma
Li, Y., Liu, H., Liu, Y., Li, J., Suzuki, H. H., Liu, Y., Jiang, T., & Qiu, X. (2025) · Chinese Neurosurgical Journal · doi:10.1186/s41016-025-00405-7 · Cited by 1
Self-citation
The potential and risks of FLASH radiotherapy in pediatric patients
Schuemann, J., Rothwell, B., Mascia, A. E., Fan, Y., Loo, B. W., Yock, T. I., Liu, K. X., Perentesis, J. P., & Haas-Kogan, D. A. (2025) · Neuro-Oncology Pediatrics · doi:10.1093/neuped/wuaf014 · Cited by 1
High-dose chemotherapy and craniospinal irradiation-sparing approach for WNT medulloblastoma of early childhood
Nobre, L. F., Ramaswamy, V., Coleman, C., Dhall, G., Senapati, A., Toledano, H., Jabado, N., Bouffet, É., & Lafay‐Cousin, L. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05425-6 · Cited by 1

Authors: Leary, S. E. S., Packer, R. J., Li, Y., Billups, C. A., Smith, K. S., Jaju, A., Heier, L., Burger, P., Walsh, K., Han, Y., Embry, L., Hadley, J., Kumar, R., Michalski, J., Hwang, E., Gajjar, A., Pollack, I. F., Fouladi, M., Northcott, P. A., & Olson, J. M.
Affiliations: Seattle Children's Hospital (US)
Children's National (US)
St. Jude Children's Research Hospital (US)
Lurie Children's Hospital (US)
Weill Cornell Medicine (US)
Johns Hopkins University (US)
The University of Texas at San Antonio Health Science Center (US)
Washington University in St. Louis (US)
Children's Hospital of Pittsburgh (US)
Nationwide Children's Hospital (US)
Corresponding author: Leary, Sarah E. S.
ORCID: Leary, Sarah E. S.
Packer, Roger J.
Li, Yimei
Billups, Catherine A.
Smith, Kyle S.
Jaju, Alok
Heier, Linda
Burger, Peter
Walsh, Karin
Han, Yuanyuan
Embry, Leanne
Hadley, Jennifer
Kumar, Rahul
Michalski, Jeff
Hwang, Eugene
Gajjar, Amar
Pollack, Ian F.
Fouladi, Maryam
Northcott, Paul A.
Olson, James M.
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2021-09-01
Volume: 7
Issue: 9
Pages: 1313
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2021.2224
PMC: PMC8299367
OpenAlex: W3184618654
Cited by: 164
References: 34
Citations by year: 2026: 25 · 2025: 50 · 2024: 27 · 2023: 34 · 2022: 17 · 2021: 11
FWCI: 12.90
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Brain Tumour Charity (GN-000575)
National Cancer Institute (R01CA114567, U10CA180899, U10CA180886)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
Keywords: high-risk medulloblastoma, carboplatin, isotretinoin, radiosensitization, event-free survival, overall survival, DNA methylation, pediatric brain tumors, maintenance chemotherapy, futility, metastatic disease, residual disease
MeSH terms: Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Cerebellar Neoplasms, Child, Child, Preschool, Humans, Male, Medulloblastoma, Isotretinoin, Carboplatin, Disease-Free Survival, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children’s Oncology Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks